2001
Analysis of Risk Factors for Fatal Rocky Mountain Spotted Fever: Evidence for Superiority of Tetracyclines for Therapy
Holman R, Paddock C, Curns A, Krebs J, McQuiston J, Childs J. Analysis of Risk Factors for Fatal Rocky Mountain Spotted Fever: Evidence for Superiority of Tetracyclines for Therapy. The Journal Of Infectious Diseases 2001, 184: 1437-1444. PMID: 11709786, DOI: 10.1086/324372.Peer-Reviewed Original ResearchConceptsRisk factorsFatal Rocky Mountain Spotted FeverRocky Mountain Spotted FeverOnset of symptomsCase fatality rateTetracycline-class antibioticsPrimary therapyClinical characteristicsOlder patientsAppropriate therapyRMSF casesNonfatal casesNational surveillanceHigh riskSpotted FeverPatientsEffective antibioticsTherapyDeathFeverAntibioticsTreatmentSymptomsFactorsDisease
1999
The Human Ehrlichioses in the United States - Volume 5, Number 5—October 1999 - Emerging Infectious Diseases journal - CDC
McQuiston J, Paddock C, Holman R, Childs J. The Human Ehrlichioses in the United States - Volume 5, Number 5—October 1999 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 1999, 5: 635-642. PMID: 10511519, PMCID: PMC2627718, DOI: 10.3201/eid0505.990504.Peer-Reviewed Original ResearchConceptsHuman granulocytic ehrlichiosisHuman monocytic ehrlichiosisInfectious Diseases journal - CDCState health departmentsPublic health importanceSerologic testingNational surveillanceHealth departmentsHuman ehrlichiosesHealth importanceDisease controlGranulocytic ehrlichiosisMonocytic ehrlichiosisEhrlichiosisUpper midwestern statesAnnual numberBetter assessmentCasesPrevention